Last reviewed · How we verify
NCT04969185: DRUMARS
Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention
trial in Malaria,Falciparum in 310 participants. Completed in 23 May 2023.
30 November 2021
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 310 |
| Start date | 16 August 2021 |
| Primary completion | 30 November 2021 |
| Estimated completion | 23 May 2023 |
| Sites | 2 locations across Burkina Faso |
Conditions studied
- Malaria,Falciparum — all drugs for Malaria,Falciparum →
Sponsor
University of California, San Francisco
Who can join
Adults 6 Months to 10, any sex, with Malaria,Falciparum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In areas of the Sahel sub-region of Africa with intense seasonal malaria transmission, seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP+AQ) has become the standard-of-care for the prevention of malaria in children. Despite the scale-up of SMC across West Africa, the malaria burden remains high. Reasons for this are not well understood, however, it is hypothesized that children eligible for SMC who get malaria may be underdosed or may have not received SP+AQ. Moreover, there are major concerns that the continued use of the SMC strategy may increase selection of AQ and/or SP-resistant Plasmodium falciparum parasites. The overall objective of this observational study are to understand the factors driving malaria among children eligible to receive SMC and whether circulating levels of sulfadoxine (SDX), pyrimethamine (PYR), and AQ are associated with risks of malaria and antimalarial drug resistance.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study.
Roh ME, Zongo I, Haro A, Huang L, et al · · 2023 · cited 14× · PMID 37221018 · DOI 10.1093/infdis/jiad172
Verify or expand the search:
- PubMed search for NCT04969185
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malaria,Falciparum
Currently open trials in the same condition.
- NCT06618885 — Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso · Phase 1 · active not recruiting
- NCT07009847 — An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine · recruiting
- NCT06524336 — Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African Children · active not recruiting
- NCT05978037 — A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines · Phase 1, PHASE2 · active not recruiting
- NCT05790889 — A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. · Phase 1, PHASE2 · recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04969185 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 14 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969185.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing